The future direction of liver transplantation for intrahepatic cholangiocarcinoma

Abstract

Liver transplantation has emerged as a potential therapeutic option for select patients with intrahepatic cholangiocarcinoma (iCCA) who are not amenable to curative resection. Recent studies have challenged the traditional notion that liver transplantation is contraindicated for iCCA, leading to a paradigm shift in its management. This review provides a comprehensive synthesis of the evidence regarding the role of liver transplantation in the treatment of very early or advanced iCCA and discusses the key challenges and future directions in this rapidly evolving field. For patients with cirrhosis and very early iCCA, liver transplantation has demonstrated excellent long-term survival rates, rivaling those of patients with hepatocellular carcinoma. However, the current transplantation criteria based on tumor size and number may be overly restrictive, excluding potential candidates who could benefit from this treatment. The incorporation of tumor markers into selection criteria may improve prognostic prediction and patient outcomes. In advanced iCCA, liver transplantation remains controversial but holds promise, especially when combined with neoadjuvant and adjuvant therapies. Donor organ scarcity necessitates the consideration of living donor liver transplantation as an alternative, while strategies such as utilizing marginal donors and exploring xenotransplantation offer potential solutions to address the shortage of donor livers. Overall, the evolving understanding of iCCA and the development of novel treatment strategies promise to refine and enhance the role of liver transplantation in the management of this challenging malignancy.

Keywords

Intrahepatic cholangiocarcinoma (ICCA) / liver transplantation / Cirrhosis / liver resection / prognosis

References

[1] Banales JM,Carpino G.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016;13:261-80

[2] Bertuccio P,Carioli G.Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.J Hepatol2019;71:104-14

[3] Mauro E,Sauri T.New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy.Cancers2023;15:1244 PMCID:PMC9953927

[4] Bridgewater J,Khan SA.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J Hepatol2014;60:1268-89

[5] Khan SA,Goldin RD.guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.Gut2012;61:1657-69

[6] Rizvi S,Hallemeier CL,Gores GJ.Cholangiocarcinoma - evolving concepts and therapeutic strategies.Nat Rev Clin Oncol2018;15:95-111

[7] Sapisochin G,Gastaca M.Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.Ann Surg2014;259:944-52

[8] Sapisochin G,Rubbia-Brandt L.Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment.Hepatology2016;64:1178-88

[9] Lunsford KE,Heyne K.Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.Lancet Gastroenterol Hepatol2018;3:337-48

[10] Pichlmayr R.Is there a place for liver grafting for malignancy?.Transplant Proc1988;20:478-482.

[11] Pichlmayr R,Tusch G.Indications and role of liver transplantation for malignant tumors.Oncologist1997;2:164-170.

[12] Schuppan D.Liver cirrhosis.Lancet2008;371:838-51 PMCID:PMC2271178

[13] Tyson GL.Risk factors for cholangiocarcinoma.Hepatology2011;54:173-84 PMCID:PMC3125451

[14] Bergquist A.Epidemiology of cholangiocarcinoma.Best Pract Res Clin Gastroenterol2015;29:221-32

[15] Palmer WC.Are common factors involved in the pathogenesis of primary liver cancers?.J Hepatol2012;57:69-76 PMCID:PMC3804834

[16] Welzel TM,Gloria G.Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.Int J Cancer2007;120:638-41

[17] Li M,Li P.Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review.J Gastroenterol Hepatol2012;27:1561-8

[18] Kang Y,Kim SH,Choi BI.Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images.Radiology2012;264:751-60

[19] Kodali S,Shekhar S,Ghobrial RM.Management of intrahepatic cholangiocarcinoma.J Clin Med2021;10:2368 PMCID:PMC8198953

[20] Sapisochin G,Roberts JP.Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma.Liver Transpl2011;17:934-42

[21] Mavros MN,Alexiou VG.Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis.JAMA Surg2014;149:565-74

[22] Reese T,Bause BA,Wagner KC.Complex liver resections for intrahepatic cholangiocarcinoma.J Clin Med2021;10:1672 PMCID:PMC8069912

[23] Mullen JT,Reddy SK.Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy.J Am Coll Surg2007;204:854-62; discussion 862

[24] Hackl C,Renner P.Liver surgery in cirrhosis and portal hypertension.World J Gastroenterol2016;22:2725-35 PMCID:PMC4777995

[25] D'Amico G,Pagliaro L.Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.J Hepatol2006;44:217-31

[26] Gerber DA.Safely expanding surgical resection for patients with hepatocellular carcinoma and cirrhosis.Dig Med Res2020;3:24-24

[27] Abbas N,Patch D. Guidance document: risk assessment of patients with cirrhosis prior to elective non-hepatic surgery. Available from: https://discovery.ucl.ac.uk/id/eprint/10167962 [Last accessed on 6 Jul 2023]

[28] Coelho FF,Fonseca GM.Laparoscopic liver resection: experience based guidelines.World J Gastrointest Surg2016;8:5-26 PMCID:PMC4724587

[29] Hyder O,Sotiropoulos GC.Recurrence after operative management of intrahepatic cholangiocarcinoma.Surgery2013;153:811-8 PMCID:PMC3980567

[30] Spolverato G,Cucchetti A.Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?.Cancer2015;121:3998-4006

[31] Lang H,Sgourakis G.Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients.J Am Coll Surg2009;208:218-28

[32] Friedman LS.Surgery in the patient with liver disease.Trans Am Clin Climatol Assoc2010;121:192-204. PMCID:PMC2917124

[33] Lieser MJ,Rowland C,Nagorney DM.Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience.J Hepatobiliary Pancreat Surg1998;5:41-7

[34] Park J,Kim KP.Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study.Gut Liver2009;3:298-305 PMCID:PMC2852727

[35] Valle J,Palmer DH.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[36] Konstantinidis IT,Do RK.Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.Cancer2016;122:758-65 PMCID:PMC4764409

[37] André T,Rosmorduc O.Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.Ann Oncol2004;15:1339-43

[38] Constance D,Samuel LS.Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.J Clin Oncol2022;40:4_suppl, 475.

[39] Ueno M,Morizane C.Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.Lancet Gastroenterol Hepatol2019;4:611-21

[40] Ziogas IA,Economopoulos KP.Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates.Transplantation2021;105:2263-71

[41] Wang Z.Adoptive cell therapy targeting neoantigens: a frontier for cancer research.Front Immunol2020;11:176 PMCID:PMC7066210

[42] Jindal V,Masab M.Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.Med Oncol2018;35:84

[43] Vignone A,Casadio M.Emerging therapies for advanced cholangiocarcinoma: an updated literature review.J Clin Med2021;10:4901 PMCID:PMC8584870

[44] Kuhlmann JB,Spangenberg HC.Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.Eur J Gastroenterol Hepatol2012;24:437-43

[45] Borakati A,Bhogal RH.Stereotactic radiotherapy for intrahepatic cholangiocarcinoma.World J Gastrointest Oncol2022;14:1478-89 PMCID:PMC9412934

[46] Takahashi K,Burmeister CS.Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis.Ann Transplant2016;21:208-15

[47] Giorgio A,DE Stefano G.Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience.Anticancer Res2011;31:4575-80.

[48] Zhang H,Wu M.Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management.Cancer Lett2016;379:198-205

[49] Smith TJ,Alesi ER.American society of clinical oncology provisional clinical opinion: the integration of palliative care into standard oncology care.J Clin Oncol2012;30:880-7

[50] Sapisochin G,Gastaca M."Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?.Am J Transplant2014;14:660-7

[51] Darwish Murad S,Harnois DM.Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.Gastroenterology2012;143:88-98.e3; quiz e14 PMCID:PMC3846443

[52] Heimbach JK,Haddock MG.Liver transplantation for unresectable perihilar cholangiocarcinoma.Semin Liver Dis2004;24:201-7

[53] Hong JC,Kaldas FM.Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma.J Am Coll Surg2011;212:514-20; discussion 520

[54] Hong JC,Duffy JP.Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center.Arch Surg2011;146:683-9

[55] Kim WR,Smith JM.OPTN/SRTR 2016 annual data report: liver.Am J Transplant2018;18 Suppl 1:172-253

[56] Hue JJ,Ammori JB.A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: an analysis of the national cancer database.J Surg Oncol2021;123:949-56

[57] Hwang S,Lee YJ.Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe.Liver Transpl2006;12:920-7

[58] Filippi R,Lombardi P.A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.Acta Oncol2021;60:1317-24

[59] Dutkowski P,Slankamenac K.Are there better guidelines for allocation in liver transplantation?.Ann Surg2011;254:745-53; discussion 753

[60] Nalesnik MA,Dimaio JM.Donor-transmitted malignancies in organ transplantation: assessment of clinical risk.Am J Transplant2011;11:1140-7

[61] Ekser B,Cooper DKC.Xenotransplantation: past, present, and future.Curr Opin Organ Transplant2017;22:513-21 PMCID:PMC5935127

[62] Northup PG,Shah NL,Berg CL.Excess mortality on the liver transplant waiting list: unintended policy consequences and model for end-stage liver disease (MELD) inflation.Hepatology2015;61:285-91